Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05075603
Title A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah) in Relapsed/Refractory Large B-cell Lymphoma Subjects
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors NeoImmuneTech
Indications

diffuse large B-cell lymphoma

B-cell lymphoma

Therapies

Tisagenlecleucel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.